Results 51 to 60 of about 160,832 (337)

Treatment patterns and cost estimations of systemic chemotherapy for pancreatic cancer in Japan: A retrospective database study

Cancer Medicine, 2023
Background This study aimed to clarify the treatment patterns of pancreatic cancer patients receiving systemic chemotherapy in Japan and to estimate the direct medical costs in actual practice.
Yuki Takumoto, Ryotaro Shibahara, Hajime Asami, Manabu Akazawa   +3 more
doaj   +1 more source

Harnessing Next‐Generation 3D Cancer Models to Elucidate Tumor‐Microbiome Crosstalk

Advanced Healthcare Materials, EarlyView.
Centralizes the microbiome within 3D tumor‐microbiome model platforms, including spheroids, organoids, 3D‐bioprinted constructs, and microfluidic chips, each enabling structured host‐tumor‐microbe studies. These systems support bacterial colonization, facilitating investigation of microbial impacts on tumor growth, immunity, and therapy. The microbiome
Marina Green Buzhor, Giuseppe Longobardi, Or Kandli, Anne Krinsky, Opal Avramoff, Anshika Katyal, Koren Salomon, Adan Miari, Dana Venkert, Tania T. Barnatan, América García Alvarado, Shahar Greenberg, Ronit Satchi‐Fainaro   +12 more
wiley   +1 more source

Long non-coding RNA LINC00665 promotes gemcitabine resistance of Cholangiocarcinoma cells via regulating EMT and stemness properties through miR-424-5p/BCL9L axis

Cell Death and Disease, 2021
Gemcitabine is the first-line chemotherapy drug for cholangiocarcinoma (CCA), but acquired resistance has been frequently observed in CCA patients. To search for potential long noncoding RNAs (lncRNAs) involved in gemcitabine resistance, two gemcitabine ...
Min Lu, Xinglei Qin, Yajun Zhou, Gang Li, Zhaoyang Liu, Xiwen Geng, Haodi Yue   +6 more
doaj   +1 more source

Molecular Simulations of Polymer‐based Drug Nanocarriers: From Physical and Structural Properties to Controlled Release

Advanced Healthcare Materials, EarlyView.
Polymer‐based drug delivery systems can effectively overcome the limitations of free drugs in terms of solubility, stability, and plasma half‐life, yet their development has traditionally relied on time‐consuming trial‐and‐error approaches. This review highlights recent advances in applying molecular simulation to the design of polymer‐based drug ...
Ping Gao, Xin Jiang, Jinyu Li, Julien Nicolas, Tâp Ha‐Duong   +4 more
wiley   +1 more source

Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment

Therapeutic Advances in Medical Oncology, 2019
Background: Chemoresistance hampers the treatment of patients suffering from pancreatic ductal adenocarcinoma (PDAC). Here we aimed to evaluate the (phospho)proteome of gemcitabine-sensitive and gemcitabine-resistant PDAC cells to identify novel ...
Tessa Ya Sung Le Large, Btissame El Hassouni, Niccola Funel, Bart Kok, Sander R. Piersma, Thang V. Pham, Kenneth P. Olive, Geert Kazemier, Hanneke W.M. van Laarhoven, Connie R. Jimenez, Maarten F. Bijlsma, Elisa Giovannetti   +11 more
doaj   +1 more source

The role of adjuvant chemotherapy for patients with resected pancreatic cancer: Systematic review of randomized controlled trials and meta-analysis [PDF]

, 2007
Background: In patients undergoing surgery for resectable pancreatic cancer prognosis still remains poor. The role of adjuvant treatment strategies (including chemotherapy and chemoradiotherapy) following resection of pancreatic cancer remains ...
Bakkevold KE, Berger AC, Blackstock AW, Cress RD, Donna Pauler Ankerst, Gastrointestinal Tumour Study Group, Hochster HS, Kalser MH, Khanna A, Knaebel HP, Kosuge T, Luttges J, Oettle H, Ozols RF, Peto R, Regine WF, Stefan Boeck, Volker Heinemann   +17 more
core   +1 more source

Rational Design of Metal–Organic Frameworks for Pancreatic Cancer Therapy: from Machine Learning Screening to In Vivo Efficacy

Advanced Materials, EarlyView.
This work explores the MOF landscape to select a single, optimal candidate for successfully delivering cancer drugs (gemcitabine, paclitaxel, SN‐38) into tough pancreatic tumors. Machine learning and simulations guide this search, demonstrating colloidal stability, excellent biocompatibility, cellular uptake, and sustained release.
Francesca Melle, Dhruv Menon, João Conniot, Jon Ostolaza‐Paraiso, Sergio Mercado, Jhenifer Oliveira, Xu Chen, Bárbara B. Mendes, João Conde, David Fairen‐Jimenez   +9 more
wiley   +1 more source

Probiotic‐Based Materials as Living Therapeutics

Advanced Materials, EarlyView.
Recent advances in Engineered Living Materials are highlighted, integrating synthetic biology and advanced materials, with a focus on probiotic‐based therapeutics. Probiotic Living Materials hold great potential for biosensing, infection treatment, osteogenesis, wound healing, vaginal and gastrointestinal disorders, and cancer therapy. breakthroughs in
Laura Sabio, Graham J. Day, Manuel Salmeron‐Sanchez   +2 more
wiley   +1 more source

Inactivation of XPF Sensitizes Cancer Cells to Gemcitabine

Journal of Nucleic Acids, 2019
Gemcitabine (2′, 2′-difluorodeoxycytidine; dFdC) is a deoxycytidine analog and is used primarily against pancreatic cancer. The cytotoxicity of gemcitabine is due to the inhibition of DNA replication.
Joseph W. George, Mika Bessho, Tadayoshi Bessho   +2 more
doaj   +1 more source

m6A eraser FTO impairs gemcitabine resistance in pancreatic cancer through influencing NEDD4 mRNA stability by regulating the PTEN/PI3K/AKT pathway

Journal of Experimental & Clinical Cancer Research, 2023
Background Gemcitabine resistance has brought great challenges to the treatment of pancreatic cancer. The N6-methyladenosine (m6A) mutation has been shown to have a significant regulatory role in chemosensitivity; however, it is not apparent whether ...
Kai Lin, Endi Zhou, Ting Shi, Siqing Zhang, Jinfan Zhang, Ziruo Zheng, Yuetian Pan, Wentao Gao, Yabin Yu   +8 more
doaj   +1 more source